Immune suppression or enhancement by CD137 T cell costimulation during acute viral infection is time dependent

Benyue Zhang,1 Charles H. Maris,1 Juergen Foell,2 Jason Whitmire,3 Liguo Niu,1 Jing Song,1 Byoung S. Kwon,4 Anthony T. Vella,5 Rafi Ahmed,1 Joshy Jacob,1 and Robert S. Mittler1

1Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia, USA. 2Department of Hematology and Oncology, Martin Luther University, Halle-Wittenberg, Germany. 3Department of Immunology, The Scripps Research Institute, La Jolla, California, USA. 4Department of Interdisciplinary Oncology and Immunomodulation Research Center, University of Ulsan, Ulsan, Republic of Korea. 5Department of Immunology, University of Connecticut Health Center, Farmington, Connecticut, USA.

CD137 is expressed on activated T cells and ligands to this costimulatory molecule have clinical potential for amplifying CD8+ T cell immunity to tumors and viruses, while suppressing CD4+ autoimmune T cell responses. To understand the basis for this dichotomy in T cell function, CD4+ and CD8+ antiviral immunity was measured in lymphocytic choriomeningitis virus (LCMV) Armstrong– or A/PR8/34 influenza–infected mice injected with anti-CD137 mAbs. We found that the timing of administration of anti-CD137 mAbs profoundly altered the nature of the antiviral immune response during acute infection. Antiviral immunity progressed normally for the first 72 hours when the mAb was administered early in infection before undergoing complete collapse by day 8 postinfection. Anti-CD137–injected LCMV-infected mice became tolerant to, and persistently infected with, LCMV Armstrong. Elevated levels of IL-10 early in the response was key to the loss of CD4+ T cells, whereas CD8+ T cell deletion was dependent on a prolonged TNF-α response, IL-10, and upregulation of Fas. Blocking IL-10 function rescued CD4 antiviral immunity but not CD8+ T cell deletion. Anti-CD137 treatment given beyond 72 hours after infection significantly enhanced antiviral immunity. Mice treated with anti-CD137 mAb 1 day before infection with A/PR8/34 virus experienced 80% mortality compared with 40% mortality of controls. When treatment was delayed until day 1 postinfection, 100% of the infected mice survived. These data show that anti-CD137 mAbs can induce T cell activation–induced cell death or enhance antiviral immunity depending on the timing of treatment, which may be important for vaccine development.

Introduction

CD137, a TNF receptor family member, is an activation-inducible T cell costimulatory receptor (1, 2) that is expressed on cells of the innate and adaptive immune system (reviewed in ref. 3). CD137 ligands induce T cell proliferation and cytokine production in vitro (4–8), whereas CD137 ligands confer potent costimulatory effects upon CD8+ T cells in vivo (9, 10). Although CD137 cross-linking costimulates CD4+ T cells to proliferate in vitro, remarkably, it suppresses the development of T cell–dependent humoral immunity in vivo (11). Both attributes have made this reagent attractive for therapeutic use in treating cancer and autoimmune disease, and it is currently being evaluated for use as an adjuvant in vaccine design (12). Herein we assess the effect of altering the timing of anti-CD137 treatment during viral infection and in so doing reconcile the dichotomy between CD137–induced CD8+ T cell activation and CD4+ T cell suppression. We found that virus-specific CD4+ and CD8+ T cell proliferation proceeds normally over the first 3 days of infection. By day 8 postinfection (P.I.), large numbers of virus-specific CD4+ and CD8+ T cells were deleted, thus leading to the loss of humoral and T cell–mediated antiviral immune responses. Anti-CD137–injected lymphocytic choriomeningitis virus–infected (LCMV-infected) mice rapidly produced high levels of IL-10 and developed sustained TNF-α production during the late stages of infection, leading to Fas expression on CD8+ T cells. Blockade of IL-10 signaling fully rescued virus-specific CD4+ T cells but minimally affected CD8+ T cell function and survival. In T cells from virus-infected anti-CD137–injected IL-10−/− mice treated with anti–TNF-α mAbs, Fas was downregulated, CD8+ T cells were not deleted, and antiviral immunity remained intact. When anti-CD137 treatment was withheld until day 4 P.I., the magnitude of antiviral immunity was significantly enhanced, demonstrating that anti-CD137 mAb treatment could induce in a time-dependent manner 2 diametrically opposed outcomes.

Results

Anti-CD137 mAb treatment during LCMV infection suppressed antiviral T cell immunity. CD137 ligands deliver costimulatory signals to CD8+ T cells in vivo and paradoxically suppress CD4+ T helper cells despite being costimulatory for both in vitro (11, 13, 14). This has raised the question of whether CD137 signaling differentially regulates CD4+ and CD8+ T cell effector function. We addressed this question in 2 viral infection models because its resolution has important ramifications for the therapeutic use of CD137 ligands. LCMV Armstrong induces an acute infection in mice that is rapidly cleared while eliciting long-lasting immunity. Antiviral immunity was measured in LCMV-infected mice given 200 μg of agonist anti-CD137 mAbs or rat IgG on day 1 P.I. Consistent with earlier reports (11, 13–15), we found that this treatment markedly suppressed CD4+ T cells as measured by T cell–dependent LCMV-spe-
cific IgG (Figure 1A), enumerating LCMV-specific antibody-secreting cells in the BM (Figure 1B) and measuring IFN-γ CD4+ T cells (Figure 1C). In dose response studies we found that 30 μg of mAb was sufficient to induce suppression when given on day 1 P.I. (data not shown). That anti-CD137 costimulates CD8+ T cells has been widely reported in the literature, and at no time has it been shown to be inhibitory. Remarkably, in this study we found complete suppression of antiviral CD8+ T cell responses. We found a marked reduction in tetramer-positive CD8+ T cells (Figure 1D), absence of IFN-γ CD8+ T cells (Figure 1F), and failure to induce antiviral CTL responses (Figure 1G). Although the CD8+ T cell response was almost completely suppressed, approximately 70% of splenic CD8+ T cells had upregulated CD43 expression, an indicator of activation (Figure 1D, middle panel), indicating that non-antigen-specific CD8+ T cells were being activated during this process. It is not known precisely how these T cells undergo activation or what the consequences of this event are. However, we have found that polyclonal T cell activation occurs in naive mice injected with anti-CD137 mAbs and that this event is dependent upon TNF-α production (16). We next tested whether suppression was linked to specific CD8 LCMV epitopes, but found that this was not the case, as dominant and subdominant immune responses were fully suppressed (Figure 1H). Suppression was not unique to the 3H3...
mAb, the epitope it recognizes, or its isotype, as other anti-CD137 mAbs differing in these characteristics produced equivalent responses (data not shown). Induction of suppression was independent of anti-CD137–mediated blocking of CD137 interaction with its ligand, as suppression occurred in LCMV-infected 4-1BB ligand–deficient mice (data not shown). The absence of antiviral T cell responses in anti-CD137–injected mice was evident in the spleen, LN, lung, and liver of treated mice (Figure 2 and data not shown). IFN-γ production had occurred as suggested in Figure 1D, then T cell deletion must have followed. To verify this we followed virus-induced CD4+ and CD8+ T cell phenotypic conversion from a naive CD44hiCD62Lhi phenotype to a CD44hiCD62Llo/− memory phenotype. On day 4 P.I. anti-CD137–injected mice had fewer CD44hiCD62Llo/− splenic CD4+ T cells than the rat IgG–injected control mice (Figure 3A). Consistent with elevated expression of CD43 on CD8+ T cells (Figure 1D), when examined on day 4 P.I. we observed increased frequencies (data not shown) and absolute cell numbers of CD44hiCD62Llo/− T cells in anti-CD137–injected mice (Figure 3B). However, by day 8 P.I. the numbers of activated memory-like CD4+ and CD8+ T cells in anti-CD137–injected mice had significantly decreased (Figure 3, C and D). CD4+ and CD8+ T cell proliferation was measured by 1 × 106 CFSE-labeled CD8+ TCR–transgenic P14 T cells and an equivalent number of CFSE–AAV–transgenic SMARTA T cells adoptively transferred into CD45.1 congenic recipients. The mice were infected and injected the following day with 200 μg of anti-CD137 or rat IgG. On days 2–4 P.I. mice were euthanized and spleen and lymph nodes were gated on CD45.2 CD4, and CD8 expression and CFSE dilution (Figure 3E). By days 2 and 3 P.I., P14 T cells and SMARTA CD4+ T cells proliferated similarly regardless of treatment. By day 4 P.I. CD4+ and CD8+ T cells in all mice had diluted their CFSE content beyond detection (data not shown). Next, CFSE-labeled P14 and SMARTA T cell recipients were injected on day 1 P.I. with anti-CD137 or rat IgG injection and euthanized at varying times and the number of splenic CFSE–CD45.2+ CD4+ and CD8+ T cells was determined. By day 4 P.I. there was a marked loss of P14 T cells in the spleens of anti-CD137–injected mice (Figure 3F). Based on Annexin V and 7AAD staining (see Anti-CD137 induced IL-10 production), it seems that this reduction in P14 T cell numbers in the spleens of anti-CD137–injected mice may represent trafficking rather than deletion.

Anti-CD137 induced persistent viral infection. To quantitate the immune response to LCMV in anti-CD137–treated mice, we used MHC class I tetramers specific for immunodominant and subdominant epitopes. We were able to identify small numbers of refracto-

![Figure 2](http://www.jci.org/). **Loss of CD8+ T cells in anti-CD137–injected virus-infected mice.** C57BL/6 mice were infected by i.p. injection of 2 × 106 PFU LCMV Armstrong. The following day, mice were injected i.p. with 200 μg of either anti-CD137 or rat IgG. Mice were euthanized on day 8 P.I. and CD8+ T cells enumerated by FACS analysis in (A) spleen, (B) pooled left and right inguinal LNs, and (C) lung.
noted between controls and anti-CD137–treated mice (data not shown). We next measured IL-10 levels in these mice because IL-10 negatively regulates Th1 immune responses (reviewed in ref. 18) and, in the case of persistent LCMV infections, blockade of IL-10 function restored antiviral immunity in these mice (19, 20). We found a rapid increase in serum IL-10 levels in LCMV-infected mice injected day 1 P.I. with anti-CD137. IL-10 was detected by day 2 P.I. and peaked by days 3–4 of infection in anti-CD137–injected mice (Figure 7A). IL-10 was not detected in LCMV-infected control mice until day 6 P.I., and then it was at much lower levels (Figure 7A). IL-10 was also not produced in uninfected anti-CD137–injected mice (data not shown). One mechanism of action for IL-10 is the deletion of virus-specific CD4+ T cells (21, 22). However, we found that cell death was minimal in CD4+ and CD8+ T cells by day 4 P.I., consistent with T cell expansion (Figure 7E), but by day 8 P.I. we observed significant apoptosis in both cell types (Figure 7B). Thus IL-10 may program virus-specific CD4+ T cell death (23) in anti-CD137–injected LCMV-infected mice. The role of IL-10 was further assessed because CD8+ T cells were also deleted, making it unclear to what extent the induction of IL-10 and deletion of CD4+ T cells contributed to anti-CD137–induced immune suppression. We determined whether anti-IL-10 receptor blocking
would prevent anti-CD137-induced suppression. This treatment had a significant effect on restoring the frequency and absolute numbers of CD44hiCD62Llo− CD8+ T cells, and this was also seen in IL-10-deficient mice where deletion of CD44hiCD62Llo− CD8+ T cells were still present (Figure 7C and data not shown). Thus IL-10 alone is responsible for the loss of CD4+ T cells in anti-CD137-injected mice. However, unlike LCMV clone 13 infection, IL-10 receptor blockade in anti-CD137-injected LCMV Armstrong-infected mice was insufficient for rescue of CD8+ T cell deletion and restoration of antiviral immunity.

TNF-α– and Fas-induced T cell death. We measured TNF-α levels in virus-infected mice because TNF-α can induce cell death and because we have previously found elevated TNF-α levels in anti-CD137–injected mice (our unpublished observations). Upon gross examination we found that spleens from infected anti-CD137–injected mice were smaller than those obtained from day 8 virus-infected controls (85–100 mg versus 160–230 mg). We also observed a 5- to 10-fold reduction in the number of CD44hiCD62Llo− T cells in anti-CD137–treated infected mice (Figure 3, C and D) and found substantial losses in the numbers of CD44hiCD62Llo− CD8+ T cells in the spleens of anti-CD137–injected virus-infected IL-10−/− mice (data not shown), suggesting that while IL-10 is not the major cause for the loss of CD8+ T cells, it nonetheless appears to be a contributing factor. Because T cell deletion can occur through TNF receptor 1–mediated and/or Fas-mediated apoptosis and TNF-α is upregulated in T cells during the late stages of LCMV infection (24), both were measured following infection. LCMV-infected mice had elevated levels of TNF-α in their serum by day 5 P.I. that subsided 24–48 hours later. In contrast, TNF-α levels in anti-CD137–injected virus-infected mice remained high through day 12 P.I., the last time point examined (Figure 8A). Supporting a role for TNF-α in the induction of suppression, we found that anti-CD137–induced suppression to LCMV was partially blunted in TNF−/− mice (Figure 8, B and C), where the mean frequency of GP33-41 tetramer-positive splenic T cells was approximately 2% compared with 5.5% for controls.

In contrast, we found the mean frequency of GP33-41 tetramer-positive splenic T cells to be 0.85% in LCMV-infected anti-CD137 injected C57BL/6 mice compared with 7.4% in LCMV-infected rat IgG–injected C57BL/6 controls. Furthermore, these changes can be seen in total numbers of GP33-41 tetramer-positive and IFN-γ–positive CD8+ T cells (Table 1). Thus not only is suppression blunted in TNF−/− mice, but also the response to LCMV infection was somewhat lower than that seen in C57BL/6 mice. TNF-α has a well-documented role in inducing T cell apoptosis regulated by RelA and NF-κB (25, 26), and it is known to induce Fas expression (27, 28). Thus IL-10 and TNF-α appear to function in tandem to induce CD4+ and CD8+ T cell apoptosis, respectively. We assessed whether T cells in LCMV-infected mice expressed Fas and found that 12% of CD8+ memory T cells from rat IgG–injected mice expressed Fas on their surface, whereas this increased to 87% in anti-CD137–injected mice (Figure 9A). To determine whether Fas was required for CD8+ T cell deletion, Fas−/− mice were infected with LCMV and injected with anti-CD137 or rat IgG on day 1 P.I. Both groups of mice were able to generate CD8+ T cell responses to LCMV epitopes with kinetics observed in wild-type mice (data not shown). However, whereas 35% of splenic CD8+ T cells from anti-CD137–treated virus-infected C57BL/6 mice were preapoptotic, apoptotic, or necrotic, only 8% of CD8+ T cells from the spleens of Fas−/− mice fell into these categories, a frequency identical to that observed in C57BL/6 virus-infected mice injected with rat IgG (Figure 9B). A similar but less dramatic result was seen in CD4+ T cells (Figure 9C). The reduction in the frequencies of apoptotic cells in Fas−/− mice was mirrored by restoration of spleen cell numbers (Figure 9D), and tetramer-positive or IFN-γ–producing CD8+ T cells (Figure 9E) in infected and treated Fas−/− mice versus C57BL/6 mice. We conclude that CD4+ T cell deletion is mediated by IL-10 signaling, whereas CD8+ T cell deletion appears to be in part dependent on IL-10 signaling and TNF-α–induced, Fas-dependent apoptosis.

Antiviral immunity in anti–TNF-α–injected anti-CD137–treated IL-10−/− mice. When anti-CD137–treated LCMV-infected IL-10−/− mice were given neutralizing anti–TNF-α mAb, we observed no loss in the numbers of splenic CD44hiCD62Llo− CD8+ T cells or LN T cells (Figure 10, A and B). We tested whether anti–TNF-α treatment of infected anti-CD137–injected IL-10−/− mice would lower Fas expression and found this to be the case (Figure 10C).

**Figure 4**
Anti-CD137–injected LCMV-infected mice remain persistently viremic. Groups of C57BL/6 mice (n = 5) were infected with LCMV Armstrong and given anti-CD137 mAbs on either day 1 or day 3 P.I. Sera were collected (coll.) on day 8 and day 100 P.I., and plaque assays were performed to detect viable virus. Chronic viral infections, included for comparison to anti-CD137–treated mice, were initiated by injecting 2 × 10^6 PFU LCMV clone 13 i.v. into mice that had also received 500 μg GK1.5 (anti-CD4) 1 day before infection. Sera from chronically infected mice were collected on day 30 P.I. The limit of detection for this assay was 500 PFU/ml.

**Figure 5**
Kinetics of anti-CD137–induced immune suppression. Groups of C57BL/6 mice (n = 5) were infected i.p. with 2 × 10^6 PFU LCMV Armstrong. One group of mice was then injected once with anti-CD137 i.p. 24 hours P.I. A second group was injected 1 day later and so on through day 5 P.I. On day 8 P.I. all groups were euthanized. (A) The percentage of GP33-41 tetramer–positive CD8+ splenic T cells was determined by FACS analysis. (B) Following in vitro GP33-41 peptide restimulation for 5 hours, the percentage of IFN-γ–producing CD8+ T cells was measured by ICS and FACS analysis. Untr, untreated.
We questioned whether anti–TNF-α would rescue antiviral immunity, and here too we found this to be the case (Figure 10, D–F). Thus anti-CD137–mediated signaling alters cytokine profiles in LCMV-infected mice. During the initial stage of infection, high levels of IL-10 are produced, and this has a deleterious effect on CD4+ T cell survival. Midway through the infection (day 5), TNF-α production was briefly upregulated in virus-infected mice, whereas anti-CD137–injected mice maintained high levels of TNF-α in their serum for at least 6 days and concurrently expressed Fas on their T cells. In the absence of IL-10 signaling, and together with neutralizing anti–TNF-α mAbs, antiviral immunity could be established in anti-CD137–injected mice.

Anti-CD137-induced suppression in influenza-infected mice. To measure anti-CD137–induced suppression in another viral infection, we assessed the ability of anti-CD137 mAbs to suppress immunity to influenza. C57BL/6 mice were intranasally infected with 6 HA units of influenza virus A/PR8/34 strain and injected with anti-CD137 or rat IgG at various time points prior to or after infection.
Progression and severity of infection was measured by weight loss and survival. Although the kinetics of anti-CD137 treatment differed from that observed in LCMV infection (day -1 versus day 1), the consequences were similar. We found that 80% of the mice injected with anti-CD137 one day prior to A/PR8/34 infection lost over 25% of their body weight and succumbed to infection (Figure 10G). In contrast, 40% of rat IgG–injected A/PR8/34-infected mice succumbed to the infection (Figure 10H). Remarkably, despite an initial loss in weight, 100% of the A/PR8/34-infected mice given anti-CD137 on day 1 P.I. (n = 5) survived the infection (Figure 10I). Thus similar to that observed in LCMV-infected mice, anti-CD137 either induced suppression or enhanced immunity depending on the timing of its administration. We do not understand the reason(s) for the shift in kinetics of anti-CD137–induced immune suppression observed between the 2 infections nor do we understand the molecular basis underlying these opposing responses, but these questions are under investigation.

Discussion

CD137 ligands are in Phase I clinical trials to treat melanoma patients, and their use will be evaluated for treating autoimmune disease and as adjuvants for vaccines. Understanding the consequences of using these reagents in vivo is therefore of considerable importance. Anti-CD137 mAbs costimulate T cells in vitro. However, in vivo use of CD137 ligands in a variety of models, and under different experimental conditions, have shown that only CD8+ T cell function is amplified or sustained as a consequence of treatment (4), in part due to upregulation of antiapoptotic genes (8, 29). In contrast, CD4+ T cell function is suppressed by anti-CD137 mAbs in normal mice (11) and following treatment of autoimmune mice (14, 15, 30), leaving unresolved the question of whether CD4+ and CD8+ T cells are differentially regulated by CD137. We addressed this question in this study using anti-CD137–injected LCMV Armstrong–infected mice in order to track virus-specific CD4+ and CD8+ T cell responses in individual mice.

Based on previously published data, we expected to find CD4+ T cell responses to be suppressed and CD8+ responses to be amplified. Remarkably, we found that CD8+ and CD4+ T cell responses to LCMV infection were, for all intents and purposes, completely suppressed. Induction of immune suppression was dependent on the timing of anti-CD137 treatment. When anti-CD137 was injected prior to infection (data not shown) or within 48 hours P.I., antiviral immunity in all lymphoid compartments and organs was suppressed. LCMV Armstrong–infected anti-CD137–treated mice became tolerant to and persistently infected with this acute strain of LCMV that is typically cleared within 2 weeks of infection. When treatment was delayed beyond 48 hours P.I., the T cell immune response was significantly enhanced, T cell–dependent humoral immunity was normal, and the mice cleared their infection with normal kinetics.

Our studies describe what we believe to be a new and unexpected role for CD137 signaling during an immune response. First, engagement of CD137 on T cells can significantly impair immune responses of CD4+ and CD8+ T cell responses; the sole difference between inducing immune suppression and enhancing antiviral immune responses in these models was found to be the timing of
The dichotomous behavior of virus- and anti-CD137–dependent during the early stages of infection. TNF-α production when anti-CD137 was injected day 1 prior to infection, the mice developed progressive and sustained weight loss, and within 12 days of infection 80% of them had succumbed to infection compared with 40% of controls. Anti-CD137–injected uninfected mice did not develop any sign of pathology. This study shows that anti-CD137 suppressed T cell–dependent autoimmune responses. Remarkably, suppression is not observed in tumor-bearing mice. And in SLE and RA mice, anti-CD137–induced immune suppression is not timing restricted (14, 32). On the surface this appears to contradict the findings of this report. However, we believe that this is not the case. Although anti-CD137 suppressed T cell–dependent autoimmune responses regardless of when it was given, this was not true when the same mice were immunized with SRBC or human IgG. In these studies, suppression was observed when anti-CD137 was given within 2 days of immunization, just as is shown in our current studies.

Table 1

<table>
<thead>
<tr>
<th>Parameter</th>
<th>C57BL/6 + rat IgG</th>
<th>TNFα+/– + rat IgG</th>
<th>C57BL/6 + anti-CD137</th>
<th>TNFα+/– + anti-CD137</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>No. total GP33-41 tetramer–positive CD8+ T cells (×10⁴)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mouse 1</td>
<td>100.4</td>
<td>139.3</td>
<td>0.9</td>
<td>10.1</td>
</tr>
<tr>
<td>Mouse 2</td>
<td>213.3</td>
<td>32.4</td>
<td>1.7</td>
<td>8.6</td>
</tr>
<tr>
<td>Mouse 3</td>
<td>89.1</td>
<td>82.1</td>
<td>1.7</td>
<td>6.7</td>
</tr>
<tr>
<td>Mouse 4</td>
<td>50.0</td>
<td>247.7</td>
<td>2.5</td>
<td>56.0</td>
</tr>
<tr>
<td>Mean</td>
<td>79.8</td>
<td>125.4</td>
<td>1.7</td>
<td>20.3</td>
</tr>
<tr>
<td>SD</td>
<td>26.4</td>
<td>92.5</td>
<td>0.7</td>
<td>23.8</td>
</tr>
<tr>
<td><strong>No. total IFNγ+/– CD8+ T cells (×10⁴)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mouse 1</td>
<td>127.9</td>
<td>483.7</td>
<td>1.6</td>
<td>11.2</td>
</tr>
<tr>
<td>Mouse 2</td>
<td>329.5</td>
<td>50.3</td>
<td>3.3</td>
<td>3.3</td>
</tr>
<tr>
<td>Mouse 3</td>
<td>123.1</td>
<td>112.4</td>
<td>1.6</td>
<td>3.5</td>
</tr>
<tr>
<td>Mouse 4</td>
<td>58.9</td>
<td>435.3</td>
<td>2.4</td>
<td>100.4</td>
</tr>
<tr>
<td>Mean</td>
<td>159.9</td>
<td>270.4</td>
<td>2.2</td>
<td>29.6</td>
</tr>
<tr>
<td>SD</td>
<td>117.4</td>
<td>220.7</td>
<td>0.8</td>
<td>47.4</td>
</tr>
</tbody>
</table>

of antigen delivery, as we saw the same outcome following i.p. and intranasal infection. We also have yet to discover which cells produce IL-10 and which produce TNF-α and whether this process is facilitated by CD137 signaling directly. Like LCMV-infected mice, A/PR8/34 influenza–infected mice given a single injection of anti-CD137 either fared worse or better than infected controls, depending on the timing of treatment. Mice injected once on day 1 P.I. or thereafter cleared the infection and regained lost weight, and unlike controls, all survived the infection. This observation is in keeping with an earlier study by Bansal-Pakala and Croft, in which they showed that a 2-day delay in treatment with anti-CD137 mAb treatment could overcome CD4+ T cell tolerance to soluble peptide in young mice and anti-CD137 administration. The overall effect leading to suppression was activation-induced cell death, in which CD4+ T cell deletion was found to be IL-10 dependent. Production of IL-10 was virus- and anti-CD137–dependent during the early stages of infection, and neither infection alone nor anti-CD137 treatment in the absence of infection induced IL-10 production or T cell deletion. In addition, sustained production of TNF-α was observed in day 1 P.I. anti-CD137–injected LCMV-infected mice but not in virus-infected controls. TNF-α production is a known consequence of LCMV Armstrong infection and occurs during the late stages of infection. Typically TNF-α production is transient and ends within 24–48 hours of onset, as can be seen in Figure 8A. In contrast, mice injected with anti-CD137 1 day P.I. maintained elevated levels of TNF-α, resulting in Fas expression on activated T cells, and this in turn led to Fas-mediated T cell apoptosis. This was shown in LCMV-infected anti-CD137 injected mice given neutralizing anti-TNF-α. Several important questions concerning the dichotomous behavior of T cells in response to CD137–mediated signals remain. For example, to what extent and for how long is IL-10 or TNF-α produced when anti-CD137 treatment is delayed to the point that it induces costimulation? And what genes are differentially regulated under these conditions? Why would T cells express CD137 so early in the activation process if its signaling induces T cell deletion? Deletion is not related to specific infectious agents or a particular class of antigen, nor is it dependent on the mode...
Anti-CD137–mediated T cell deletion is Fas dependent. (A) Anti-CD137 increased Fas expression on CD8⁺ T cells; relative cell numbers are shown. C57BL/6 mice were infected with LCMV and injected with anti-CD137 or rat IgG on day 1 P.I., and on day 8 P.I. splenic CD8⁺ T cells were gated on CD44⁺CD62L⁻/⁻ cells and phenotyped for Fas expression. C57BL/6 or Fas-deficient mice were infected with LCMV and injected with anti-CD137 or rat IgG on day 1 P.I. On day 8 P.I. the mice (n = 5) were euthanized and the frequency of splenic CD8⁺ (B) and CD4⁺ (C) T cells undergoing cell death were measured. Numbers in B and C are percentages. PI, propidium iodide. (D) The absolute number of surviving spleen cells was measured. (E) The absolute numbers of GP33-41 tetramer–positive CD8⁺ T cells and IFN-γ⁺ CD8⁺ T cells following 5 hours of in vitro GP33-41 restimulation are shown.
In autoimmune mice T cell-dependent autoreactive responses are continuously generated due to epitope spreading and/or T and/or B cell exhaustion. Under such conditions we would suggest that newly initiated autoreactive responses were being “nipped in the bud” during antigen priming. In this scenario, T cell exhaustion induced by constant exposure to autoantigens limits the lifespan of these cells that are refractive to anti-CD137. This is not an unreasonable premise, as T cell exhaustion has been described in mice persistently infected with LCMV (33, 34).

In the case of immune responses to tumor antigens, we find that CD8⁺ T cell responses, unlike antiviral responses, are not suppressed, but in these situations the mice had been inoculated and tumors allowed to grow prior to anti-CD137 treatment. Thus treatment was not administered during first exposure to antigen. Whether this is an accurate interpretation of why anti-CD137 treatment induces suppression remains to be determined. We do not know why CD137-mediated signals program T cells toward death or whether this process is physiologically relevant. However, it seems that the T cell is not prepared to receive this early signal through CD137, and this leads to cell death. It is conceivable that anti-CD137 mAbs are inducing activation and at the same time blocking CD137 receptor-ligand interactions necessary for T cell survival. However, studies in 41BBL−/− mice argue against this interpretation—but this would not hold true if a second, as yet unidentified ligand for CD137 was required for this function.

From DNA microarrays we have found marked changes in CD4⁺ and CD8⁺ T cell gene expression in LCMV-infected mice given rat IgG or anti-CD137 on day 1 P.I., and these data are currently being evaluated. Regardless of mechanisms involved, the outcomes reported in this study might have an important bearing on the development of CD137 ligand-based immunotherapies. An alternative explanation is that anti-CD137 mAbs have a much higher avidity for CD137 than its ligand (4-1BBL). Indeed, the avidity of the 3H3 mAb used in this study is higher than the soluble ligand by 2 orders of magnitude (10⁻¹⁳ M versus 10⁻⁸ M, respectively). However, we do not believe this is the case because we have produced a panel of anti-CD137 mAbs having avidities that range from 10⁻¹⁰ M to 10⁻¹² M and all behave similarly (4-8). Moreover, the avidity of APC-bound 4-1BBL for CD137 is almost certainly greater than the soluble 4-1BBL fusion protein. Perhaps a more likely explanation is that anti-CD137 mAbs induce modulation of key costimulatory receptors from the cell surface, or modulates their signaling activity and these events disturb necessary activation pathways for sustaining early activation and antigen priming. We are currently investigating this possibility.

**Methods**

**Mice and antibodies.** C57BL/6 8- to 12-week-old female mice, C57BL/6 CD45.1 congenic mice, Rag2−/−, IL10−/−, TNFα−/−, or Fas−/− mice on a C57BL/6 background were purchased from The Jackson Laboratory. C57BL/6 LCMV GP33–41-specific TCR-transgenic Rag−/− mice were purchased from Taconic Farms. C57BL/6 CD137−/− mice were generated as previously described (35). Jacques Peschon (Immunex Corp., Seattle, Washington, USA) generously provided 4-1BBL ligand−/− mice. Mice were housed at the Yerkes National Primate Research Center Vivarium, Emory University. All animal studies reported herein were approved by the Emory University Institutional Animal Care and Use Committee (IACUC). Neutralizing anti-TNF-α mAbs (2E2) were obtained from the NCI Biological Resource Branch, and anti–IL-10R mAbs were produced from the 1-B1-3A hybridoma provided by Drew Pardoll (Johns Hopkins University, Baltimore, Maryland, USA). The 3H3 clone, a rat IgG₂a anti-mouse CD137 agonistic mAb, and the 9D6 clone, a rat IgG₂a anti-human CD137 mAb were produced as described in refs. 4 and 36. C57BL/6 mice were injected i.p. with 200 μg anti-CD137 or rat IgG at various time points as described in Results. Control groups were treated initially with anti-human CD137 mAb (9D6) and later with rat IgG.

**Virus infections.** C57BL/6 mice were infected i.p. with 2 × 10⁵ PFU of the Armstrong CA 1371 strain of LCMV or i.v. with 2 × 10⁴ PFU of the clone 13 variant of LCMV (37). Infectious LCMV in serum and tissues was quantitated by plaque assay on Vero cell monolayers, as described previously (38). C57BL/6 mice were infected with 6 HA units of influenza virus strain A/PB/34/1947 in mice administered i.n. 25 μl/naris.

**CD8 tetramer and FACS staining.** H-2Db tetramers bound to LCMV peptide GP33–41, NP396–404, NP205–212, GP276–286, or GP92–101 were prepared previously (23). PBMCs or spleen cells were stained with allophycocyanin-conjugated H-2Db GP33–41 or NP396–404 tetramers, and fluorochrome-conjugated monoclonal anti-mouse CD8 was purchased from BD Pharmingen and analyzed by flow cytometry.

**Intracellular staining for IFNγ.** Intracellular IFN-γ staining has been described previously (23). PBMCs or spleen cells were stimulated in vitro with medium, GP33–41, or NP396–404 at 1 μg/ml for 5 hours with Golgiplug (BD Biosciences). Cells were stained with PerCP-conjugated monoclonal anti-CD8 (BD Biosciences) and stained for intracellular IFN-γ according to the manufacturer’s recommended protocol. FITC-conjugated or allophycocyanin-conjugated monoclonal rat anti-mouse IFN-γ and control isotype Ab (rat IgG₁) from BD Biosciences were used for intracellular IFN-γ staining.
CTL assays. MHC class I–restricted LCMV-specific CTL activity was determined ex vivo by 11Cr release assay as previously described (38). MC57 target cells were either infected with LCMV or preincubated for 30 minutes with individual viral peptides as indicated in the legend for Figure 1 (10 μg/ml).

ELISA measurements. Sera were collected as indicated in the legends for Figures 1, 7, and 8. Lysates of LCMV-infected or infected BHK-21 cells were generated and bound to microtiter plates overnight at 4°C. Plates were washed 3 times with PBS plus 0.5% FBS and 0.5% Triton X-100. Serum from preimmune or immune mice with or without anti-CD137 treatment was allowed to bind for 90 minutes at room temperature. Bound LCMV-specific IgG was detected with HRP-conjugated goat α-mouse IgG and visualized by HRP substrate (R&D Systems) as described previously (39). Serum cytokine measurements were performed using ELISA kits from BioLegend following the manufacturer’s instructions.

Anti–TNF-α treatment of IL-10–deficient mice. IL-10–/– mice were infected with LCMV at day 0 and injected on day 1 P.I. with 200 μg rat IgG or anti-CD137 plus 300 μg anti-TNF-α. On day 8 P.I. the mice were sacrificed and splenocytes were stained with fluorochrome-conjugated mAbs to T cell antigens, CD95 (Fas), and MHC class I tetramers containing the LCMV-specific peptide GP33-41. Cells were permeabilized and intracellularly stained with allophtocyanin-conjugated anti-IFN-γ mAb after restimulation with LCMV-specific GP33-41 or NP396-404 peptides for 5 hours at 37°C.

Flow cytometry and data processing. PBMCs, and spleen and lymph node cells were isolated and blocked with 10 μg/ml anti-CD16/anti-CD32 (clone 2.4G2; ATCC) for 10 minutes in PBS supplemented with 1.5% BSA and 0.05% sodium azide. FACS analysis was carried out on a BD FACSCalibur or LSRII multiparameter flow cytometer (BD Biosciences). Aliquots with allophycocyanin-conjugated anti–IFN-γ and with EY13325 (to B.S. Kwon); by the Cancer Research Institute (to C.H. Marias); and by the SRC Fund from KISER and Korean MOST (to B.S. Kwon).

Received for publication April 17, 2007, and accepted in revised form June 27, 2007.

Address correspondence to: Robert S. Mittler, Emory Vaccine Center, Emory University School of Medicine, 954 Gatewood Rd. NE, Atlanta, Georgia 30329, USA. Phone: (404) 727-9425; Fax: (404) 727-8199; E-mail: mittler@emory.edu.

Charles H. Marias’s present address is: Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA.

Benyue Zhang, Charles H. Marias, and Juergen Foell contributed equally to this work.

30. Seo, S.K., et al. 2004. 4-1BB-mediated immunotherap-